Chemistry:Razpipadon
From HandWiki
Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.[1][2][3][4] It is taken orally.[1]
Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors.[1][2][5] The drug has been found to increase willingness to exert effort for rewards in humans and hence appears to show pro-motivational effects.[6][7]
The drug was originated by Pfizer and is under development by Cerevel Therapeutics.[1] As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "CVL 871 - AdisInsight". https://adisinsight.springer.com/drugs/800058095.
- ↑ 2.0 2.1 "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci 3 (6): 1042–1062. December 2020. doi:10.1021/acsptsci.0c00117. PMID 33344888.
- ↑ "Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease". Expert Opin Emerg Drugs: 1–15. June 2024. doi:10.1080/14728214.2024.2363215. PMID 38822731.
- ↑ "An Update on Apathy in Alzheimer's Disease". Geriatrics 8 (4): 75. July 2023. doi:10.3390/geriatrics8040075. PMID 37489323.
- ↑ "CVL-871 - Cerevel Therapeutics". 2 January 2020. https://www.cerevel.com/compounds/cvl-871/.
- ↑ "Using pharmacological manipulations to study the role of dopamine in human reward functioning: A review of studies in healthy adults". Neurosci Biobehav Rev 120: 123–158. January 2021. doi:10.1016/j.neubiorev.2020.11.004. PMID 33202256. "Similarly, augmenting DA using a D1 agonist (PF-06412562; 6mg, 15mg, 30mg) increased willingness to exert physical effort for reward (Soutschek et al., 2020).".
- ↑ "Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences". Biol Psychiatry 87 (7): 678–685. April 2020. doi:10.1016/j.biopsych.2019.09.002. PMID 31668477.
External links
 |  |
